Has AI delivered on its promise in pharma supply chains?

21 May 2024
2020_pills_tablets_bottles_biotech_manufacturing_production_big

This week's Expert View comes from Steve Brownett-Gale (pictured below), marketing lead at British pharmaceutical packaging firm Origin.

The use of AI across all industries and sectors has been heralded as driving efficiency and accelerating innovation, with some  experts even citing the technology as the biggest disruptor of our lifetime.

This is certainly true for big pharma, with generative AI expected to generate  $60 billion to $110 billion annually for pharmaceutical sectors.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical